| Trial ID: | L4447 |
| Source ID: | NCT00466518
|
| Associated Drug: |
Administration Of Sitagliptin
|
| Title: |
Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Transplant|Type 2 Diabetes
|
| Interventions: |
DRUG: Administration of sitagliptin
|
| Outcome Measures: |
Primary: Changes in pharmacokinetics, 3 months | Secondary: To determine if there is a change in side effects with the addition of sitagliptin to the post-kidney transplant treatment regime., 3 months|To determine the effect of sitagliptin on glucose lowering over 3 months as measured by the change in HgbA1c., 3 months|To determine if the addition of sitagliptin changes tacrolimus or sirolimus drug levels in post-kidney transplant patients, 3 months|Determine tolerability of sitagliptin therapy in post-kidney transplant patients., 3 months
|
| Sponsor/Collaborators: |
Sponsor: University of Oklahoma
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
16
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-04
|
| Completion Date: |
2011-01
|
| Results First Posted: |
|
| Last Update Posted: |
2017-06-05
|
| Locations: |
University of Nebraska Medical Center, Omaha, Nebraska, 68198-1230, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00466518
|
